BioSpace News Archive

2022 Conference Developed by McKesson and Health Mart Focuses on “Charting the Future of Community Pharmacy”.

IN8bio, Inc., a clinical-stage biopharmaceutical company focused on the discovery and development of innovative gamma-delta T cell therapies utilizing its DeltEx platform, announced an appointment to its executive team to lead the Company’s business development efforts.

Incyte announced that it has scheduled its second quarter financial results conference call and webcast for 8:00 a.m. ET on Tuesday, August 2, 2022.

BioCardia ® , Inc. [Nasdaq: BCDA], Sunnyvale, Calif. – BioCardia ® , Inc. [Nasdaq: BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today announced that Company’s CEO Peter Altman has been invited to participate at two upcoming therapeutic development symposia.

Clinilabs Drug Development Corporation (“Clinilabs”), a global, full-service contract research organization with deep expertise in central nervous system drug development, announced today that enrollment has begun in a Phase 1/2a clinical trial of CYB003, the first novel psilocybin analog to be evaluated in Phase 1/2a development for the treatment of major depressive disorder (“MDD”).

Histopathology Data of Preclinical Repeated Dose Toxicity Study and ex vivo Human Tissue Cross-Reactivity (TCR) Analysis Support Safety of IPA’s PolyTope® TATX-03, a Synergistic Antibody Cocktail against SARS ‑CoV‑2.

GlycoEra AG announced today key appointments of biotech industry leaders to its Board of Directors, including Georges Gemayel , Ph.D., as Chair, as well as Philippe Dro , Ph.D., M.B.A., and Kush Parmar, M.D., Ph.D.

Kiromic BioPharma, Inc. (NASDAQ: KRBP) (“Kiromic” or the “Company”), a clinical-stage fully integrated biotherapeutics company using its proprietary DIAMOND ® artificial intelligence and data mining platform to develop cell and gene therapies with a focus on immuno-oncology, announces the appointment of Leonardo Mirandola, Ph.D., as Chief Scientific Officer, effective immediately.

Bioventus Inc. (Nasdaq: BVS) (“Bioventus” or the “Company”), a global leader in innovations for active healing, announced today that it has completed its acquisition of CartiHeal.

NanoVibronix, Inc. , (NASDAQ: NAOV), a medical device company utilizing the Company’s proprietary and patented low intensity surface acoustic wave (SAW) technology, today announced its Australian distributor, DukeHill HC, is launching a series of educational webinars to present the Company’s UroShield technology to clinicians.